Detalhe da pesquisa
1.
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
N Engl J Med
; 366(3): 207-15, 2012 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22256804
2.
The EGF receptor Hokey-Cokey.
Cancer Cell
; 11(3): 209-11, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17349577
3.
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.
Bioorg Med Chem
; 21(5): 1284-304, 2013 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23376011
4.
Small molecule inhibitors of BRAF in clinical trials.
Bioorg Med Chem Lett
; 22(2): 789-92, 2012 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22222036
5.
Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow.
Org Process Res Dev
; 25(1): 148-156, 2021 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33679122
6.
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.
Bioorg Med Chem
; 18(18): 6934-52, 2010 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20667740
7.
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
J Med Chem
; 63(5): 2308-2324, 2020 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31430136
8.
Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.
Nat Commun
; 10(1): 3151, 2019 Jul 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31320631
9.
Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships.
J Med Chem
; 62(12): 5863-5884, 2019 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31070916
10.
Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.
J Med Chem
; 51(11): 3261-74, 2008 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-18473434
11.
Long functionalized poly(ethylene glycol)s of defined molecular weight: synthesis and application in solid-phase synthesis of conjugates.
Bioconjug Chem
; 19(4): 973-81, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18380471
12.
Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.
Nat Commun
; 8: 14909, 2017 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28416796
13.
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.
J Med Chem
; 49(1): 407-16, 2006 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-16392826
14.
V599EB-RAF is an oncogene in melanocytes.
Cancer Res
; 64(7): 2338-42, 2004 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15059882
15.
B-RAF is a therapeutic target in melanoma.
Oncogene
; 23(37): 6292-8, 2004 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-15208680
16.
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Cancer Cell
; 27(1): 85-96, 2015 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25500121
17.
Structure-activity relationship in cationic lipid mediated gene transfection.
Curr Med Chem
; 10(14): 1233-61, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12678797
18.
Synthesis of novel cationic lipids: effect of structural modification on the efficiency of gene transfer.
J Med Chem
; 45(1): 99-114, 2002 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-11754582
19.
Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
J Med Chem
; 46(9): 1690-705, 2003 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-12699387
20.
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.
Sci Signal
; 7(318): ra30, 2014 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-24667377